Immune Checkpoint Inhibitors in Patients With NSCLC and Brain Metastases

Immune checkpoint inhibitors (ICI) targeting PD-1 and PD-L1 are a standard treatment for metastatic non-small cell lung cancer (NSCLC) across multiple lines of therapy for patients who do not possess targetable driver mutations. While as many as 40% of patients with advanced NSCLC will develop brain metastases during the course of their disease, patients with […]

Read More

No Value for Lymphadenectomy in Advanced Ovarian Cancer

Most patients with ovarian cancer are diagnosed in an advanced stage. The standard of care for these patients is maximal cytoreductive surgical debulking, followed by systemic treatment including platinum-based chemotherapy and targeted therapies (eg, bevacizumab, olaparib maintenance in patients harboring BRCA mutations). The goal of primary surgical cytoreduction is removal of as much of the […]

Read More

Improving Healthcare Delivery in Immuno-Oncology via QI Initiatives

Cancer care is complex and rapidly evolving and providing high quality of cancer care for all patients with cancer is an important goal of healthcare providers worldwide. Treatment of cancer has been recently revolutionized with the introduction of immunotherapy, such as immune checkpoint inhibitors, that has demonstrated durable responses and improved survival in various cancers, […]

Read More